Their only condition, Gregg says, was that the contracts be clear that if any patients were harmed by liver toxicity due to the medicine, Bristol would not be liable.
Gemayel says that aside from the giveaway, Roche has a clear marketing message for the new treatment, which combats hepatitis C virus and the chronic liver disease it causes.